Author

B. Bajrami

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Hilpmann· 1 shared A. Ianari· 1 shared A. Kramm· 1 shared A. L. Eheim· 1 shared A. Skepner· 1 shared B. J. McMillan· 1 shared C. Montagnon· 1 shared D. C. McKinney· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. Hilpmann

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Discovery of a first-in-class inhibitor of the PRMT5-substrate adaptor interaction

D. C. McKinney, B. J. McMillan, M. Ranaghan, J. A. Moroco, M. Brousseau, Z. Mullin-Bernstein, M. O'Keefe, P. McCarren, M. F. Mesleh, K. M. Mulvaney, R. Singh, B. Bajrami, A. Skepner, D. E. Timm, D. Porter, , A. Ianari

The paper identifies a first-in-class inhibitor, BRD0639, that targets the PRMT5-PBM interaction, disrupting SAP binding and reducing substrate methylation in cancer cells.

bioRxiv · Feb 3, 2021 · PreprintCancer Biology

Targeting a Therapy-Resistant Cancer Cell State Using Masked Electrophiles as GPX4 Inhibitors

J. K. Eaton, L. Furst, R. A. Ruberto, D. Moosmayer, R. C. Hillig, A. Hilpmann, K. Zimmermann, M. J. Ryan, M. Niehues, V. Badock, A. Kramm, S. Chen, P. A. Clemons, S. Gradl, C. Montagnon, , S. L. Schreiber

This paper identifies nitrile oxide electrophiles as a new class of GPX4 inhibitors that overcome limitations of existing chloroacetamide-based inhibitors.

bioRxiv · Sep 5, 2018Biochemistry